Cytokinetics
CYTK · NASDAQ
$63.95+$1.30 (+2.08%)TodayMarket closed ·
Prev close $62.65
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 8.2% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$1.44
- Revenue estimate
- $40.83M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.67 | -$1.50 | +10.4% |
| Q1 FY26 | -$1.69 | -$1.67 | +0.9% |
| Q4 FY25 | -$1.49 | -$1.50 | −1.0% |
| Q3 FY25 | -$1.61 | -$2.55 | −58.2% |
| Q2 FY25 | -$1.40 | -$1.12 | +20.3% |
| Q1 FY25 | -$1.41 | -$1.39 | +1.4% |
| Q4 FY24 | -$1.22 | -$1.26 | −3.6% |
| Q3 FY24 | -$1.27 | -$1.36 | −6.8% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- Citigroup’s Biopharma Back to School Summit 2026
- Special Call - Cytokinetics, Incorporated
- CYTK - Earnings call Q2 2026
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Shareholder/Analyst Call - Cytokinetics, Incorporated
- CYTK - Earnings call Q1 2026
- Special Call - Cytokinetics, Incorporated
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.